Arbutus Biopharma (ABUS) Misses Q3 EPS by 10c

Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.49), $0.10 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• ON Semiconductor (ON) PT Lowered to $90 at Cantor Fitzgerald After Analyst Day
• Citi upgrades Haemonetics to Buy, raises price target to $123